文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

改良呋塞米反应指数与生物标志物预测急性肾损伤进展及预后:一项前瞻性观察性研究

Modified furosemide responsiveness index and biomarkers for AKI progression and prognosis: a prospective observational study.
PubMed 文献 · Ann Intensive Care · 2024-10-08
一句话结论心脏术后轻中度AKI患者中,mFRI预测AKI进展、进展至3期及死亡/RRT复合结局的AUC分别为0.80、0.87、0.85,与新型肾损伤生物标志物相当或更优。

该单中心前瞻性研究纳入心脏术后48小时内发生KDIGO 1–2期AKI的患者1013例,在AKI诊断时测量mFRI(2小时尿量除以呋塞米剂量与体重)、sNGAL、uNGAL、血清胱抑素C、uNAG、尿白蛋白肌酐比及多种细胞因子。154例(15.2%)AKI进展,59例(5.8%)进展至3期,33例(3.3%)达到住院死亡或接受RRT复合结局。mFRI预测AKI进展、进展至3期及复合结局的AUC分别为0.80(95%CI 0.77–0.82)、0.87(95%CI 0.85–0.89)、0.85(95%CI 0.82–0.87),不劣于或可能优于肾损伤生物标志物与细胞因子;mFRI联合uNAG或uNGAL较单一标志物显著改善预测(均P<0.05),加入临床模型后C指数、综合判别改善及净重分类改善均显著提高(均P<0.05)。作者认为mFRI快速、经济、易获取,对心脏术后轻中度AKI患者的进展和预后具有优于或相当于肾损伤生物标志物的预测能力。

要点

  • 心脏术后48小时内KDIGO 1–2期AKI患者中,mFRI预测AKI进展的AUC为0.80(95%CI 0.77–0.82)。
  • mFRI预测进展至KDIGO 3期的AUC为0.87(95%CI 0.85–0.89),预测住院死亡或RRT复合结局的AUC为0.85(95%CI 0.82–0.87)。
  • mFRI联合尿损伤标志物uNAG或uNGAL,对不良肾脏结局的预测较任一单一标志物显著改善(均P<0.05)。
  • 将mFRI与尿损伤标志物组合纳入临床模型后,C指数、综合判别改善和净重分类改善均显著提高(均P<0.05)。
  • 1013例中154例(15.2%)AKI进展,59例(5.8%)进展至3期,33例(3.3%)达到死亡或RRT复合结局。

适用人群与场景

  • 心脏手术后48小时内发生初始轻至中度AKI(KDIGO 1至2期)的患者,单中心前瞻性纳入,共1013例。

诊断标准与关键阈值

  • AKI分期采用KDIGO标准,纳入初始KDIGO 1至2期患者。
  • mFRI定义为2小时尿量除以呋塞米剂量与体重。

研究设计与关键结果

  • 研究类型为单中心前瞻性观察性研究,纳入心脏术后48小时内KDIGO 1–2期AKI患者1013例,在AKI诊断时测量mFRI、sNGAL、uNGAL、血清胱抑素C、uNAG、尿白蛋白肌酐比及细胞因子(TNF、IL-1β、IL-2R、IL-6、IL-8、IL-10)。
  • 154例(15.2%)发生AKI进展,59例(5.8%)进展至3期,33例(3.3%)达到住院死亡或接受RRT的复合结局。
  • mFRI预测AKI进展的AUC为0.80(95%CI 0.77–0.82),预测进展至3期的AUC为0.87(95%CI 0.85–0.89),预测死亡或RRT复合结局的AUC为0.85(95%CI 0.82–0.87),对肾损伤生物标志物和细胞因子显示不劣于或可能更优。
  • mFRI联合uNAG或uNGAL较任一单一标志物显著改善对不良肾脏结局的预测(均P<0.05)。
  • 将上述组合纳入临床模型后,C指数、综合判别改善和净重分类改善均显著提高(均P<0.05)。

证据类型、等级与局限

  • 证据类型:单中心前瞻性观察性研究。

对床旁实践的改变

  • 作者认为,mFRI作为快速、经济、易获取的生物标志物,在心脏术后轻至中度AKI患者中对AKI进展和预后的预测能力优于或相当于肾损伤生物标志物。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Modified furosemide responsiveness index (mFRI) is a novel biomarker for assessing diuretic response and AKI progression in patients with early AKI. However, the comparative predictive performance of mFRI and novel renal biomarkers for adverse renal outcomes remains unclear. In a single-center prospective study, we aimed to evaluate the discriminatory abilities of mFRI and other novel renal biomarkers in predicting AKI progression and prognosis in patients with initial mild and moderate AKI (KDIGO stage 1 to 2).

RESULTS: Patients with initial mild and moderate AKI within 48 h following cardiac surgery were included in this study. The mFRI, renal biomarkers (including serum or urinary neutrophil gelatinase-associated lipocalin [sNGAL or uNGAL], serum cystatin C, urinary N-acetyl-beta-D-glycosaminidase [uNAG], urinary albumin-to-creatinine ratio) and cytokines (TNF, IL-1β, IL-2R, IL-6, IL-8, and IL-10) were measured at AKI diagnosis. The mFRI was calculated for each patient, which was defined as 2-hour urine output divided by furosemide dose and body weight. Of 1013 included patients, 154 (15.2%) experienced AKI progression, with 59 (5.8%) progressing to stage 3 and 33 (3.3%) meeting the composite outcome of hospital mortality or receipt of renal replacement therapy (RRT). The mFRI showed non-inferiority or potential superiority to renal biomarkers and cytokines in predicting AKI progression (area under the curve [AUC] 0.80, 95% confidence interval [CI] 0.77-0.82), progression to stage 3 (AUC 0.87, 95% CI 0.85-0.89), and composite outcome of death and receipt of RRT (AUC 0.85, 95% CI 0.82-0.87). Furthermore, the combination of a functional biomarker (mFRI) and a urinary injury biomarker (uNAG or uNGAL) resulted in a significant improvement in the prediction of adverse renal outcomes than either individual biomarker (all P < 0.05). Moreover, incorporating these panels into clinical model significantly enhanced its predictive capacity for adverse renal outcomes, as demonstrated by the C index, integrated discrimination improvement, and net reclassification improvement (all P < 0.05).

CONCLUSIONS: As a rapid, cost-effective and easily accessible biomarker, mFRI, exhibited superior or comparable predictive capabilities for AKI progression and prognosis compared to renal biomarkers in cardiac surgical patients with mild to moderate AKI.

TRIAL REGISTRATION: Clinicaltrials.gov, NCT04962412. Registered July 15, 2021, https://clinicaltrials.gov/ct2/show/NCT04962412?cond=NCT04962412&draw=2&rank=1 .

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Su Y, Liu WJ, Zhao YF, et al. Modified furosemide responsiveness index and biomarkers for AKI progression and prognosis: a prospective observational study. Ann Intensive Care. 2024. PMID: 39379672. doi:10.1186/s13613-024-01387-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。